Ilorasertib has been used in trials studying the treatment of Myelodysplasia, Solid Neoplasm, Advanced Cancers, Advanced Solid Tumors, and Acute Myelogenous Leukemia, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ilorasertib. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ilorasertib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ilorasertib. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ilorasertib. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Ilorasertib. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Ilorasertib is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Ilorasertib is combined with Etrasimod. |